News Madrigal eyes combination MASH therapy with Pfizer deal Madrigal Pharma is reheating a drug for metabolic dysfunction-associated steatohepatitis (MASH) put on ice by Pfizer last year.
News Madrigal closes on EU approval of first MASH treatment Madrigal Pharma could be just weeks away from becoming the first drugmaker to claim EU approval for a MASH treatment.
News Madrigal Pharma is first over the MASH finish line Madrigal Pharma has become the first drugmaker to claim FDA approval for a drug to treat metabolic dysfunction-associated steatohepatitis (MASH), an elusive target that ha
News Lilly inflates US facility investment spending by $4.5bn Having already committed last year to capital investments of $27 billion in the US to ward off the threat of tariffs, Eli Lilly has upped the ante.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
